Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that the U.S. Food and Drug Administration has granted Fast ...

Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when ...

A groundbreaking study from the University of Cambridge reveals a new drug that can significantly reduce brain damage caused ...

US FDA grants fast track designation to Revalesio’s lead investigational therapy, RNS60 to treat acute ischemic stroke: Tacoma, Washington Saturday, August 2, 2025, 15:00 Hrs [I ...

Stroke is the second leading cause of death globally. Ischemic stroke, strongly linked to atherosclerotic plaques, requires ...

ETB, is expected to enroll over 500 patients with a primary endpoint of proportion of patients demonstrating functional independence at 90 days and is being conducted under a Special Protocol ...

Berhampur: Prompt intervention by doctors at MKCG Medical College and Hospital here helped save a 49-year-old assistant ...

CHI Memorial is proud to announce it is the first hospital in the world to enroll a patient in a Phase 3 clinical trial evaluating a promising new treatment for ischemic stroke. This groundbreaking ...

Stroke is the second leading cause of death globally. Ischemic stroke, strongly linked to atherosclerotic plaques, requires accurate plaque and vessel ...

Novel nomogram models predict early neurological deterioration and 90-day outcomes in AIS patients treated with IV ...

A research team led by Professor Lee Kyung-yeol and Jeong Yo-han of Yonsei University's Gangnam Severance Hospital confirmed ...